Bladder Cancer

Different types of cancer can start in the bladder, such as urothelial carcinoma and squamous cell carcinoma. Alfa Cytology is a world leader in the research of cancer. With our extensive experience and advanced platform, we can provide the best solutions for bladder cancer.

Introduction to Bladder Cancer

Bladder cancer occurs when cells in the bladder begin to grow uncontrollably. Urothelial carcinoma, also known as transitional cell carcinoma, is a kind of cancer that begins with urothelial cells and is the most common type of bladder cancer. Other types of bladder cancer, such as squamous cell carcinoma, adenocarcinoma, and small cell carcinoma, are relatively rare. According to the latest data, bladder cancer accounts for 3% of global cancer diagnoses, especially in developed countries.

Therapy Development for Bladder Cancer

Bladder cancer is a complex and challenging disease. Here are some cutting-edge therapies that have emerged in recent years.

Targeted Therapy

Bladder cancer usually involves gene changes that drive tumor growth. Specific molecular targets include fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), and programmed death ligand 1 (PD-L1).

FGFR inhibitor-Erdafitinib

Antibody Drug Conjugate

Antibody drug conjugate (ADC) is an innovative therapy that combines the specificity of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs. Balversa (erdafitinib) and Padcev (efortumab vedotin) are examples of ADC that show efficacy in advanced bladder cancer.

Gene Therapy

Gene therapy can alter the genetic composition of tumor cells. A common method of gene therapy is to use viral vectors to directly deliver therapeutic genes to cancer cells, targeting specific oncogenes or enhancing immune responses to malignant cells.

Several pharmaceutical companies and research institutions are actively developing drugs and therapies for bladder cancer.

Targets	Therapeutics	Company	Molecule Type	Phase
LAG-3	Favezelimab + pembrolizumab (MK-4280a)	Merck	Monoclonal antibody
PDL1	Atezolizumab (RG7446)	Roche	Monoclonal antibody

Our Services

Bladder cancer is a highly heterogeneous disease and easy to recur, facing multiple challenges and difficulties. Therefore, Alfa Cytology is working on providing one-stop solutions for bladder cancer, including but not limited to the following.

Therapeutics Development Services

Diagnostic Development Services

Preclinical Research
Services

Models of Bladder Cancer

As a provider of comprehensive scientific research services, Alfa Cytology offers a range of animal model options specifically designed for bladder cancer research. These models are crucial in understanding disease mechanisms, evaluating therapy outcomes, and developing new therapy strategies.

In Vitro	In Vivo
Cell Line Organoid Scaffold-Based Model 3D-Bioprinted Bladder Cancer-On-A-Chip Tissue-Engineered Model	Patient-Derived Xenograft Model Cell Line-Derived Xenograft Model Carcinogen-Induced Model Genetically Engineered Model Tumor Metastatic Model Preconditioned Animal Model

Alfa Cytology is committed to the research and study of cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for bladder cancer. If you are interested in our service, please contact us for more information.

For research use only.